Cisco Systems Inc vs Summit Therapeutics Inc — how do they compare? Cisco Systems Inc trades at $123.9 (market cap $474.67B), while Summit Therapeutics Inc trades at $15.09 (market cap $12.06B). The key difference: Cisco Systems Inc is far larger — about 39.4× Summit Therapeutics Inc's market cap, and Cisco Systems Inc pays a 1.4% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CSCO | SMMT | |
|---|---|---|
Market Cap | $474.67B | $12.06B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $26.98 |
52-Week Low | $66.20 | $12.55 |
Enterprise Value | $489.33B | $11.39B |
Dividend Yield | 1.4% | — |
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.
CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Latest headlines on both assets
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →